Reimbursement Support
Align with dynamic reimbursement guidelines, lower costs, and see more patients with simple on-site molecular testing that fits your existing team.
Overview
Our molecular system supports CPT 87637 billing of multiplex molecular respiratory pathogen detection (typically SARS CoV 2, influenza A, influenza B, and RSV). When performed in a physician office, clinic, or urgent care setting, claims are generally processed under Medicare Part B clinical laboratory billing rules.
Key Billing Requirements
Report the Correct CPT Code
- Recommended CPT and LOINC codes can be found at CodeMap®.
Include Modifier QW (When Applicable)*
- CMS assigns CLIA‑waived edits to certain laboratory codes.
- CPT 87637 is subject to QW reporting requirements when billed as a waived test.
Official CMS Reference:
CMS MLN Matters – QW Modifier Guidance
*Modifier QW indicates a Clinical Laboratory Improvement Amendment (CLIA) waived test performed by a lab with a CLIA certificate.
Report the CLIA Certificate Number
- Medicare requires a valid CLIA number for clinical laboratory testing.
- The CLIA number must be included on claims for laboratory services.
Proper Claim Form Placement
- CMS 1500 (Paper Claims): Report CLIA number in Item 23.
- Electronic Claims (837P): Report CLIA number in the designated REF segment.
Common Causes of Claim Denials
Missing
Modifier QW
Missing or Invalid CLIA Number
CLIA Certificate Type Mismatch
Incorrect Place of Service
Payer-Specific Billing Considerations
Helpful Medicare Contractor Resources
Operational guidance frequently used by billing teams:
Palmetto GBA – CLIA Certification Number Requirements
Novitas – Modifier QW Fact Sheet
Private Payer Billing Considerations
While Medicare rules often drive billing workflows, private payers may apply different edits and requirements.
- Modifier usage may vary by payer
- Prior authorization requirements may apply
- Panel size or target restrictions may exist
- Contracted rates govern payment (not CLFS)
Practical Reminder
Billing requirements are separate from coverage policies. Always verify:
- CLIA certification status of performing site
- Payer-specific
This information is provided for general billing education only and does not constitute reimbursement or legal advice. Providers are responsible for accurate coding, documentation, and compliance with Medicare regulations.
Medicaid Billing Considerations
Medicaid programs are state-specific and frequently differ from Medicare requirements.
- Modifier QW requirements may vary
- State fee schedules determine payment
- Managed Medicaid plans may apply commercial-style edits
- Prior authorization may be required
Molecular Testing Launch - First 90 Days Readiness Roadmap
Foundation & Readiness
DAYS 1–30
Goal: establish organizational and strategic foundations
Establish Internal Ownership
- Clinical lead
- Revenue cycle lead
- Compliance oversight
- LIS/IT support
Understand Your Payer Landscape
- Identify your Medicare Administrative Contractor (MAC)
- Review applicable Local Coverage Determinations (LCDs)
- Identify top commercial payers mix & review applicable coverage and billing policies
- Review CPT code descriptors via American Medical Association
- Review Medicare policy resources from Centers for Medicare & Medicaid Services
Operational Preparation
- Validate systems (LIS, code mapping)
- Confirm charge master setup
- Align documentation workflows
Workflow Validation & Controlled Go-Live
Days 31–60
Goal: test processes before full launch
Documentation Readiness
- Confirm medical necessity capture
- Validate requisition completeness
- Align reflex/add-on workflows (if applicable)
Revenue Cycle Testing
- Conduct test claim submissions
- Monitor clearinghouse acceptance
- Validate remittance workflows
- Identify potential rejection triggers
Denial Preparedness
- Establish an appeal process framework
- Implement denial tracking dashboard
- Identify documentation retrieval process
Monitor, Optimize, & Stabilize
Days 61–90
Goal: improve performance and stabilize operations
Early Performance Monitoring
- Clean claim rate
- Denial rate by payer
- Payment turnaround time
- Appeal overturn trends
Policy Surveillance
- Monitor LCD updates
- Track commercial payer policy revisions
- Stay current on coding education resources (e.g., American Academy of Professional Coders)
90-Day Review
- Financial performance vs expectations
- Operational bottlenecks
- Education needs for ordering providers
- Scale readiness assessment
Frequently Asked Questions
This information is provided for general billing education only and does not constitute reimbursement or legal advice. Providers are responsible for accurate coding, documentation, and compliance with Medicare regulations.
CPT 87637 represents multiplex molecular detection of respiratory pathogens, typically including SARS CoV 2, influenza A, influenza B, and RSV.
Yes. CPT 87637 may be billed when testing is performed in a CLIA certified physician office, clinic, or urgent care setting.
Yes. The testing location must hold an appropriate CLIA certificate matching the complexity level of the test.
When billed as a CLIA waived test, modifier QW is typically required. Modifier requirements may vary by payer.
Yes. A valid CLIA certificate number must be included on claims for laboratory testing.
- CMS 1500 (paper claims): Item 23
- Electronic claims (837P): REF segment
POS selection depends on where the test is performed. Common examples include:
- POS 11 – Physician Office
- POS 20 – Urgent Care Facility
- POS 22 – Hospital Outpatient Department
Always verify payer specific POS guidance.
The performing laboratory bills for the test. The collecting provider may bill specimen collection when appropriate.
Typical denial drivers include:
- Missing modifier QW
- Missing or invalid CLIA number
- CLIA certificate mismatch
- Incorrect POS
- Payer specific bundling edits
Not always. Commercial insurers frequently apply different modifier edits, prior authorization requirements, and payment rules.
Not necessarily. Medicaid requirements are state specific and may differ from Medicare and commercial policies.
- CLIA certification status
- Modifier requirements
- CLIA number accuracy
- POS selection
- Prior authorization rules (if applicable)
Public Resource Pathways
Official Coding & CPT Resources
- American Medical Association (AMA) CPT Coding Resources:
General CPT code sets and coding resources (definitions, guidelines, tools): AMA CPT® Coding Resources (American Medical Association). - AMA Molecular Pathology Tier 2 Codes:
Overview of recently released molecular pathology CPT codes: Molecular Pathology Tier 2 Codes (AMA). - AMA CPT® PLA Codes:
Information about Proprietary Laboratory Analysis (PLA) codes and descriptors: CPT® PLA Codes (American Medical Association). - AMA CPT PLA FAQs:
Background on how PLA codes work and their use in reporting tests: FAQs: CPT® PLA Codes (AMA).
Coverage Policy & Medicare Tools
- Medicare Coverage Database:
Searchable repository of Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), coverage articles, coding & billing policy, and contractor documentation: Medicare Coverage Database Search (CMS).
This site lets users find LCDs, coding & coverage articles by keyword, CPT code, or jurisdiction — a foundational resource for coverage policy exploration. - How to Use the Medicare Coverage Database (CMS):
CMS guidance explaining coverage document types and how to navigate the MCD: How to Use the Medicare Coverage Database (CMS MLN). - Clinical Laboratory Fee Schedule (CLFS):
Medicare’s official lab fee schedule listing test codes and payment amounts; files available for download: CMS Clinical Laboratory Fee Schedule (CLFS). - CLFS Data Files:
Specific quarterly release files with clinical lab codes and Medicare payment data: CLFS Files by CMS. - Local Coverage Determinations Overview (CMS):
Explanation of what LCDs are and how they affect coverage decisions: Local Coverage Determinations (CMS).
Professional Association Resources
- AMP Coverage & Reimbursement Resources:
Educational materials and background on molecular coding, coverage, reimbursement, and policy advocacy: Coverage & Reimbursement (Association for Molecular Pathology).